|
[1]
|
Siegel, R.L., Wagle, N.S., Star, J., Kratzer, T.B., Smith, R.A. and Jemal, A. (2026) Colorectal Cancer Statistics, 2026. CA: A Cancer Journal for Clinicians, 76, e70067. [Google Scholar] [CrossRef]
|
|
[2]
|
Siegel, R.L., Kratzer, T.B., Wagle, N.S., Sung, H. and Jemal, A. (2026) Cancer Statistics, 2026. CA: A Cancer Journal for Clinicians, 76, e70043. [Google Scholar] [CrossRef]
|
|
[3]
|
Matsuda, T., Fujimoto, A. and Igarashi, Y. (2025) Colorectal Cancer: Epidemiology, Risk Factors, and Public Health Strategies. Digestion, 106, 91-99. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Siegel, R.L., Wagle, N.S. and Jemal, A. (2026) Leading Cancer Deaths in People Younger than 50 Years. JAMA, 335, 632-634. [Google Scholar] [CrossRef]
|
|
[5]
|
Mahvi, D.A., Liu, R., Grinstaff, M.W., Colson, Y.L. and Raut, C.P. (2018) Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies. CA: A Cancer Journal for Clinicians, 68, 488-505. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
陈顺, 仵朝晖, 解有成, 等. 局部进展期结直肠癌新辅助免疫治疗临床研究及应用进展[J]. 中国肿瘤临床, 2023, 50(2): 92-97.
|
|
[7]
|
Yeh, C., Wheless, M.C., Ciombor, K.K. and Cercek, A. (2026) New Frontiers in the Treatment of Rectal Cancer. Annual Review of Medicine, 77, 177-192. [Google Scholar] [CrossRef]
|
|
[8]
|
Smith, H.G., Nilsson, P.J., Shogan, B.D., Harji, D., Gambacorta, M.A., Romano, A., et al. (2024) Neoadjuvant Treatment of Colorectal Cancer: Comprehensive Review. BJS Open, 8, zrae038. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Liu, S., Jiang, T., Xiao, L., Yang, S., Liu, Q., Gao, Y., et al. (2021) Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and meta-Analysis. The Oncologist, 26, e1555-e1566. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
林振宇, 张鹏, 汪海虹, 等. 错配修复功能完整和(或)微卫星稳定型局部进展期直肠癌患者短程放疗序贯化疗联合免疫治疗的新辅助治疗专家共识(2025版) [J]. 实用肿瘤杂志, 2025, 40(5): 391-399.
|
|
[11]
|
杨慧, 穆晓峰, 宋丽楠, 等. 局部晚期直肠癌新辅助放化疗后完全缓解的相关临床因素分析[J]. 中国辐射卫生, 2026, 35(1): 6-11.
|
|
[12]
|
Kanani, A., Veen, T. and Søreide, K. (2021) Neoadjuvant Immunotherapy in Primary and Metastatic Colorectal Cancer. British Journal of Surgery, 108, 1417-1425. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Yang, Z., Wu, G., Zhang, X., Gao, J., Meng, C., Liu, Y., et al. (2022) Current Progress and Future Perspectives of Neoadjuvant Anti-PD-1/PD-L1 Therapy for Colorectal Cancer. Frontiers in Immunology, 13, Article 1001444. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Yu, I., Dakwar, A. and Takabe, K. (2023) Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer. Cells, 12, Article 258. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Uehara, K., Matsuda, A., Yamada, T., Monkhonsupphawan, A. and Yoshida, H. (2025) Total Neoadjuvant Therapy for Rectal Cancer: Why Japan Says “Not Yet”. Annals of Gastroenterological Surgery, 10, 305-314. [Google Scholar] [CrossRef]
|
|
[16]
|
Aguilera, M.J.S., Gaspá, F.L., González-Flores, E., Mirón, M.L.L., Mozo, J.L.M., del Carmen Riesco Martínez, M., et al. (2025) SEOM-GEMCAD-TTD Clinical Guidelines for Localized Rectal Cancer (2025). Clinical and Translational Oncology, 28, 451-462. [Google Scholar] [CrossRef]
|
|
[17]
|
Capdevila, J., Gómez, M.A., Guillot, M., Páez, D., Pericay, C., Safont, M.J., et al. (2022) SEOM-GEMCAD-TTD Clinical Guidelines for Localized Rectal Cancer (2021). Clinical and Translational Oncology, 24, 646-657. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Hurst, P.A., Prout, W.G., Kelly, J.M., Bannister, J.J. and Walker, R.T. (1982) Local Recurrence after Low Anterior Resection Using the Staple Gun. Journal of British Surgery, 69, 275-276. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Knol, J. and Keller, D.S. (2020) Total Mesorectal Excision Technique—Past, Present, and Future. Clinics in Colon and Rectal Surgery, 33, 134-143. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Heald, R.J. and Ryall, R.D.H. (1986) Recurrence and Survival after Total Mesorectal Excision for Rectal Cancer. The Lancet, 327, 1479-1482. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
McCall, J.L., Cox, M.R. and Wattchow, D.A. (1995) Analysis of Local Recurrence Rates after Surgery Alone for Rectal Cancer. International Journal of Colorectal Disease, 10, 126-132. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Tocchi, A., Mazzoni, G., Lepre, L., Liotta, G., Costa, G., Agostini, N., et al. (2001) Total Mesorectal Excision and Low Rectal Anastomosis for the Treatment of Rectal Cancer and Prevention of Pelvic Recurrences. Archives of Surgery, 136, 216-220. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Heald, R.J., Moran, B.J., Ryall, R.D.H., Sexton, R. and MacFarlane, J.K. (1998) Rectal Cancer. Archives of Surgery, 133, 894-899. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Ryu, H.S., Kim, H.J., Kang, D.H., Kwak, Y., Kwak, H.D., Kwon, Y., et al. (2026) The Korean Rectal Cancer Multidisciplinary Committee Clinical Practice Guidelines for Rectal Cancer Version 2.0. Annals of Coloproctology, 42, 4-33. [Google Scholar] [CrossRef]
|
|
[25]
|
Benson, A.B., Venook, A.P., Adam, M., Chang, G., Chen, Y., Ciombor, K.K., et al. (2024) NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network, 22, 366-375. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Påhlman, L. and Glimelius, B. (1990) Pre-or Postoperative Radiotherapy in Rectal and Rectosigmoid Carcinoma Report from a Randomized Multicenter Trial. Annals of Surgery, 211, 187-195. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Swedish Rectal Cancer Trial, Cedermark, B., Dahlberg, M., Glimelius, B., Påhlman, L., Rutqvist, L.E., et al. (1997) Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer. New England Journal of Medicine, 336, 980-987. [Google Scholar] [CrossRef]
|
|
[28]
|
Thomschke, D., Kyau-Ummen, B. and Halbfaß, H.J. (2002) Lokalrezidiv-und Überlebensraten nach Rektumkarzinomoperationen und multimodaler Therapie. Der Chirurg, 73, 245-254. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Bosset, J., Calais, G., Mineur, L., Maingon, P., Stojanovic-Rundic, S., Bensadoun, R., et al. (2014) Fluorouracil-Based Adjuvant Chemotherapy after Preoperative Chemoradiotherapy in Rectal Cancer: Long-Term Results of the EORTC 22921 Randomised Study. The Lancet Oncology, 15, 184-190. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., et al. (2004) Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. New England Journal of Medicine, 351, 1731-1740. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Sebag-Montefiore, D., Stephens, R.J., Steele, R., Monson, J., Grieve, R., Khanna, S., et al. (2009) Preoperative Radiotherapy versus Selective Postoperative Chemoradiotherapy in Patients with Rectal Cancer (MRC CR07 and NCIC-CTG C016): A Multicentre, Randomised Trial. The Lancet, 373, 811-820. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
张一宁, 王宏伟. 低位直肠癌新辅助治疗研究进展[J]. 消化肿瘤杂志(电子版), 2025, 17(4): 532-537.
|
|
[33]
|
Bujko, K., Nowacki, M.P., Nasierowska-Guttmejer, A., Michalski, W., Bebenek, M. and Kryj, M. (2006) Long-term Results of a Randomized Trial Comparing Preoperative Short-Course Radiotherapy with Preoperative Conventionally Fractionated Chemoradiation for Rectal Cancer. British Journal of Surgery, 93, 1215-1223. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Ngan, S.Y., Burmeister, B., Fisher, R.J., Solomon, M., Goldstein, D., Joseph, D., et al. (2012) Randomized Trial of Short-Course Radiotherapy versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients with T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. Journal of Clinical Oncology, 30, 3827-3833. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Bhudia, J. and Glynne-Jones, R. (2022) The Evolving Neoadjuvant Treatment Paradigm for Patients with Locoregional Mismatch Repair Proficient Rectal Cancer. Current Treatment Options in Oncology, 23, 453-473. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Conroy, T., Bosset, J., Etienne, P., Rio, E., François, É., Mesgouez-Nebout, N., et al. (2021) Neoadjuvant Chemotherapy with FOLFIRINOX and Preoperative Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 702-715. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Jin, J., Tang, Y., Hu, C., Jiang, L., Jiang, J., Li, N., et al. (2022) Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (Stellar). Journal of Clinical Oncology, 40, 1681-1692. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Dijkstra, E.A., Nilsson, P.J., Hospers, G.A.P., Bahadoer, R.R., Meershoek-Klein Kranenbarg, E., Roodvoets, A.G.H., et al. (2023) Locoregional Failure during and after Short-Course Radiotherapy Followed by Chemotherapy and Surgery Compared with Long-Course Chemoradiotherapy and Surgery: A 5-Year Follow-Up of the RAPIDO Trial. Annals of Surgery, 278, e766-e772. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Schrag, D., Shi, Q., Weiser, M.R., Gollub, M.J., Saltz, L.B., Musher, B.L., et al. (2023) Preoperative Treatment of Locally Advanced Rectal Cancer. New England Journal of Medicine, 389, 322-334. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Basch, E., Dueck, A.C., Mitchell, S.A., Mamon, H., Weiser, M., Saltz, L., et al. (2023) Patient-Reported Outcomes during and after Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). Journal of Clinical Oncology, 41, 3724-3734. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Deng, Y., Chi, P., Lan, P., Wang, L., Chen, W., Cui, L., et al. (2016) Modified FOLFOX6 with or without Radiation versus Fluorouracil and Leucovorin with Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. Journal of Clinical Oncology, 34, 3300-3307. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Emile, S.H. and Wignakumar, A. (2024) Non-Operative Management of Rectal Cancer: Highlighting the Controversies. World Journal of Gastrointestinal Surgery, 16, 1501-1506. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Habr-Gama, A. and Perez, R.O. (2009) Non-Operative Management of Rectal Cancer after Neoadjuvant Chemoradiation. British Journal of Surgery, 96, 125-127. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Habr-Gama, A., Perez, R.O., Nadalin, W., Sabbaga, J., Ribeiro, U., Silva e Sousa, A.H., et al. (2004) Operative versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy: Long-Term Results. Annals of Surgery, 240, 711-718. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Chiloiro, G., Meldolesi, E., Giraffa, M., Capocchiano, N.D., Barbaro, B., Coco, C., et al. (2021) Could the Conservative Approach Be Considered Safe in the Treatment of Locally Advanced Rectal Cancer in Case of a Clinical Near-Complete or Complete Response? A Retrospective Analysis. Clinical and Translational Radiation Oncology, 28, 1-9. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Dattani, M., Heald, R.J., Goussous, G., Broadhurst, J., São Julião, G.P., Habr-Gama, A., et al. (2018) Oncological and Survival Outcomes in Watch and Wait Patients with a Clinical Complete Response after Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Systematic Review and Pooled Analysis. Annals of Surgery, 268, 955-967. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Dossa, F., Chesney, T.R., Acuna, S.A. and Baxter, N.N. (2017) A Watch-And-Wait Approach for Locally Advanced Rectal Cancer after a Clinical Complete Response Following Neoadjuvant Chemoradiation: A Systematic Review and Meta-analysis. The Lancet Gastroenterology & Hepatology, 2, 501-513. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Bujko, K., Pietrzak, L., Partycki, M., Szczepkowski, M., Wyrwicz, L., Rupiński, M., et al. (2017) The Feasibility of Short-Course Radiotherapy in a Watch-And-Wait Policy for Rectal Cancer. Acta Oncologica, 56, 1152-1154. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Nilsson, P.J., Ahlberg, M., Kordnejad, S., Holm, T. and Martling, A. (2021) Organ Preservation Following Short-Course Radiotherapy for Rectal Cancer. BJS Open, 5, zrab093. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Garcia-Aguilar, J., Patil, S., Gollub, M.J., Kim, J.K., Yuval, J.B., Thompson, H.M., et al. (2022) Organ Preservation in Patients with Rectal Adenocarcinoma Treated with Total Neoadjuvant Therapy. Journal of Clinical Oncology, 40, 2546-2556. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Rullier, E., Rouanet, P., Tuech, J., Valverde, A., Lelong, B., Rivoire, M., et al. (2017) Organ Preservation for Rectal Cancer (GRECCAR 2): A Prospective, Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet, 390, 469-479. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Calmels, M., Labiad, C., Lelong, B., Lefevre, J.H., Tuech, J., Benoist, S., et al. (2023) Local Excision after Neoadjuvant Chemoradiotherapy for Mid and Low Rectal Cancer: A Multicentric French Study from the GRECCAR Group. Colorectal Disease, 25, 1973-1980. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Bach, S.P., Gilbert, A., Brock, K., Korsgen, S., Geh, I., Hill, J., et al. (2021) Radical Surgery versus Organ Preservation via Short-Course Radiotherapy Followed by Transanal Endoscopic Microsurgery for Early-Stage Rectal Cancer (TREC): A Randomised, Open-Label Feasibility Study. The Lancet Gastroenterology & Hepatology, 6, 92-105. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Cunningham, C. (2023) Local Excision for Early Rectal Cancer. Clinical Oncology, 35, 82-86. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Peltrini, R., Sacco, M., Luglio, G. and Bucci, L. (2020) Local Excision Following Chemoradiotherapy in T2-T3 Rectal Cancer: Current Status and Critical Appraisal. Updates in Surgery, 72, 29-37. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R., Iveson, T., et al. (2020) Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 31, 1291-1305. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Vogel, J.D., Felder, S.I., Bhama, A.R., Hawkins, A.T., Langenfeld, S.J., Shaffer, V.O., et al. (2022) The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Diseases of the Colon & Rectum, 65, 148-177. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Nair, K.G., Kamath, S.D., Chowattukunnel, N. and Krishnamurthi, S.S. (2024) Preoperative Strategies for Locally Advanced Colon Cancer. Current Treatment Options in Oncology, 25, 376-388. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Smith, H.G., Skovgaards, D.M., Bui, N.H., Chiranth, D., Qvortrup, C. and Schlesinger, N.H. (2023) Differences in Adjuvant Chemotherapy and Oncological Outcomes According to Margin Status in Patients with Stage III Colon Cancer. Acta Oncologica, 62, 594-600. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Gosavi, R., Chia, C., Michael, M., Heriot, A.G., Warrier, S.K. and Kong, J.C. (2021) Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer: A Systematic Review and Meta-analysis. International Journal of Colorectal Disease, 36, 2063-2070. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Seymour, M.T., Maughan, T.S., Ledermann, J.A., Topham, C., James, R., Gwyther, S.J., et al. (2007) Different Strategies of Sequential and Combination Chemotherapy for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS): A Randomised Controlled Trial. The Lancet, 370, 143-152. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Taieb, J., Tabernero, J., Mini, E., Subtil, F., Folprecht, G., Van Laethem, J., et al. (2014) Oxaliplatin, Fluorouracil, and Leucovorin with or without Cetuximab in Patients with Resected Stage III Colon Cancer (PETACC-8): An Open-Label, Randomised Phase 3 Trial. The Lancet Oncology, 15, 862-873. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Karoui, M., Rullier, A., Piessen, G., Legoux, J.L., Barbier, E., De Chaisemartin, C., et al. (2020) Perioperative FOLFOX 4 versus FOLFOX 4 Plus Cetuximab versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22). Annals of Surgery, 271, 637-645. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Karoui, M., Gallois, C., Piessen, G., Legoux, J., Barbier, E., De Chaisemartin, C., et al. (2021) Does Neoadjuvant FOLFOX Chemotherapy Improve the Prognosis of High‐risk Stage II and III Colon Cancers? Three Years’ Follow‐Up Results of the PRODIGE 22 Phase II Randomized Multicentre Trial. Colorectal Disease, 23, 1357-1369. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
FOxTROT Collaborative Group (2012) Feasibility of Preoperative Chemotherapy for Locally Advanced, Operable Colon Cancer: The Pilot Phase of a Randomised Controlled Trial. The Lancet Oncology, 13, 1152-1160. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Seligmann, J.F., Morton, D., Elliott, F., Handley, K., Gray, R., Seymour, M., et al. (2025) Neo-Adjuvant FOLFOX with and without Panitumumab for Patients with Kras-WT Locally Advanced Colon Cancer: Results Following an Extended Biomarker Panel on the Foxtrot Trial Embedded Phase II Population. Annals of Oncology, 36, 520-528. [Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Morton, D., Seymour, M., Magill, L., Handley, K., Glasbey, J., Glimelius, B., et al. (2023) Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. Journal of Clinical Oncology, 41, 1541-1552. [Google Scholar] [CrossRef] [PubMed]
|
|
[68]
|
Sargent, D.J., Marsoni, S., Monges, G., Thibodeau, S.N., Labianca, R., Hamilton, S.R., et al. (2010) Defective Mismatch Repair as a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. Journal of Clinical Oncology, 28, 3219-3226. [Google Scholar] [CrossRef] [PubMed]
|
|
[69]
|
Castria, T.B.d., Lenz, G., Valagni, G. and Kim, R.D. (2025) Role of Neoadjuvant Therapies in Locally Advanced Colon Cancer. Chinese Medical Journal, 138, 2091-2101. [Google Scholar] [CrossRef] [PubMed]
|
|
[70]
|
练达, 侯代鑫, 刘鲲鹏, 姜昊, 谢鹏宇. 腹腔热灌注化疗的研究进展[J]. 临床医学进展, 2026, 16(4): 3295-3304.
|
|
[71]
|
Arjona-Sánchez, A., Espinosa-Redondo, E., Gutiérrez-Calvo, A., Segura-Sampedro, J.J., Pérez-Viejo, E., Concepción-Martín, V., et al. (2023) Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial. JAMA Surgery, 158, 683-691. [Google Scholar] [CrossRef] [PubMed]
|
|
[72]
|
Morris, V.K., Kennedy, E.B., Baxter, N.N., Benson, A.B., Cercek, A., Cho, M., et al. (2023) Treatment of Metastatic Colorectal Cancer: ASCO Guideline. Journal of Clinical Oncology, 41, 678-700. [Google Scholar] [CrossRef] [PubMed]
|
|
[73]
|
Hamm, J.J.M., van den Berg, R., Andrinopoulou, E.R., Zwanenburg, E.S., Musters, G.D., Tanis, P.J., et al. (2025) Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients with Colon Cancer at High Risk of Peritoneal Metastases: Individual Patient Data Meta-Analysis. British Journal of Surgery, 112, znaf076.
|
|
[74]
|
Arjona-Sánchez, A., Gutiérrez-Calvo, A., Segura-Sampedro, J.J., Morales, R., Pérez-Viejo, E., Concepción-Martín, V., et al. (2026) Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colorectal Cancer (HIPECT4): Final Analysis of Randomized Clinical Trial. BJS Open, 10, zrag002. [Google Scholar] [CrossRef]
|
|
[75]
|
李檞, 孙龙和, 邹嘉诚, 等. 细胞减灭术联合腹腔热灌注化疗治疗T3~4期结直肠癌患者的临床疗效[J]. 实用临床医药杂志, 2025, 29(23): 129-135.
|
|
[76]
|
邢雅军. 腹腔灌注化疗联合全身静脉化疗治疗结直肠癌合并恶性腹腔积液的效果及安全性分析[J]. 大医生, 2024, 9(17): 24-26.
|
|
[77]
|
李福, 任宝清, 郭晨媛, 等. 预防性腹腔热灌注化疗治疗结直肠癌的临床研究[J]. 中国肿瘤临床, 2024, 51(24): 1267-1272.
|
|
[78]
|
Sugarbaker, P.H. (2023) A Narrative Review of What Can HIPEC Do. European Journal of Surgical Oncology, 49, Article ID: 106976. [Google Scholar] [CrossRef] [PubMed]
|
|
[79]
|
Baratti, D., Kusamura, S., Azmi, N., Guaglio, M., Montenovo, M. and Deraco, M. (2020) Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery with or without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). Annals of Surgical Oncology, 27, 98-106. [Google Scholar] [CrossRef] [PubMed]
|
|
[80]
|
Winicki, N.M. and Greer, J.B. (2024) Is Hyperthermic Intraperitoneal Chemotherapy Appropriate for Colon Cancer? Advances in Surgery, 58, 49-64. [Google Scholar] [CrossRef] [PubMed]
|
|
[81]
|
Rovers, K.P., Bakkers, C., Nienhuijs, S.W., Burger, J.W.A., Creemers, G.M., Thijs, A.M.J., et al. (2021) Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial. JAMA Surgery, 156, 710-720. [Google Scholar] [CrossRef] [PubMed]
|
|
[82]
|
Wisselink, D.D., Braakhuis, L.L.F., Gallo, G., van Grevenstein, W.M.U., van Dieren, S., Kok, N.F.M., et al. (2019) Systematic Review of Published Literature on Oxaliplatin and Mitomycin C as Chemotherapeutic Agents for Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Metastases from Colorectal Cancer. Critical Reviews in Oncology/Hematology, 142, 119-129. [Google Scholar] [CrossRef] [PubMed]
|
|
[83]
|
van Stein, R.M., Aalbers, A.G.J., Sonke, G.S. and van Driel, W.J. (2021) Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review. JAMA Oncology, 7, 1231-1238. [Google Scholar] [CrossRef] [PubMed]
|
|
[84]
|
Alhumaidan, S.S., Alharbi, A.M., Syeda, A.F., Alghaidani, F.A., Almutairi, M.M., Alharbi, N.A., et al. (2022) Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery for Colorectal Peritoneal Carcinomatosis Patients: A Review. Cureus, 14, e32440. [Google Scholar] [CrossRef] [PubMed]
|
|
[85]
|
丁健. 肿瘤的精准治疗与挑战[J]. 中国药理学与毒理学杂志, 2019, 33(10): 755.
|
|
[86]
|
Ganesh, K., Stadler, Z.K., Cercek, A., Mendelsohn, R.B., Shia, J., Segal, N.H., et al. (2019) Immunotherapy in Colorectal Cancer: Rationale, Challenges and Potential. Nature Reviews Gastroenterology & Hepatology, 16, 361-375. [Google Scholar] [CrossRef] [PubMed]
|
|
[87]
|
Galon, J. and Bruni, D. (2019) Approaches to Treat Immune Hot, Altered and Cold Tumours with Combination Immunotherapies. Nature Reviews Drug Discovery, 18, 197-218. [Google Scholar] [CrossRef] [PubMed]
|
|
[88]
|
Yang, C., Zhao, L., Lin, Y., Wang, S., Ye, Y. and Shen, Z. (2024) Improving the Efficiency of Immune Checkpoint Inhibitors for Metastatic PMMR/MSS Colorectal Cancer: Options and Strategies. Critical Reviews in Oncology/Hematology, 200, Article ID: 104204. [Google Scholar] [CrossRef] [PubMed]
|
|
[89]
|
Kang, W., Zhang, Z., Li, W., Zhang, Q., Li, N., Jiang, Y., et al. (2026) Breaching the Immune-Cold Barrier in PMMR/MSS Metastatic Colorectal Cancer: Emerging Strategies Beyond Standard Care. Frontiers in Immunology, 17, Article 1773002. [Google Scholar] [CrossRef]
|
|
[90]
|
Xiao, B., Yu, J. and Ding, P. (2023) Nonoperative Management of DMMR/MSI-H Colorectal Cancer Following Neoadjuvant Immunotherapy: A Narrative Review. Clinics in Colon and Rectal Surgery, 36, 378-384. [Google Scholar] [CrossRef] [PubMed]
|
|
[91]
|
Thibodeau, S.N., Bren, G. and Schaid, D. (1993) Microsatellite Instability in Cancer of the Proximal Colon. Science, 260, 816-819. [Google Scholar] [CrossRef] [PubMed]
|
|
[92]
|
Xie, Y., Liao, L., Ding, P. and Jiang, W. (2026) Discordance between Radiological and Pathological Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer: A Meta-Analysis. Frontiers in Immunology, 17, Article 1680500. [Google Scholar] [CrossRef]
|
|
[93]
|
Lenz, H., Van Cutsem, E., Luisa Limon, M., Wong, K.Y.M., Hendlisz, A., Aglietta, M., et al. (2022) First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II Checkmate 142 Study. Journal of Clinical Oncology, 40, 161-170. [Google Scholar] [CrossRef] [PubMed]
|
|
[94]
|
Boland, C.R. and Goel, A. (2010) Microsatellite Instability in Colorectal Cancer. Gastroenterology, 138, 2073-2087.e3. [Google Scholar] [CrossRef] [PubMed]
|
|
[95]
|
Llosa, N.J., Cruise, M., Tam, A., Wicks, E.C., Hechenbleikner, E.M., Taube, J.M., et al. (2015) The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. Cancer Discovery, 5, 43-51. [Google Scholar] [CrossRef] [PubMed]
|
|
[96]
|
Diaz Jr., L.A. and Le, D.T. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 373, 1979. [Google Scholar] [CrossRef]
|
|
[97]
|
Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., et al. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 372, 2509-2520. [Google Scholar] [CrossRef] [PubMed]
|
|
[98]
|
André, T., Shiu, K., Kim, T.W., Jensen, B.V., Jensen, L.H., Punt, C., et al. (2020) Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. New England Journal of Medicine, 383, 2207-2218. [Google Scholar] [CrossRef] [PubMed]
|
|
[99]
|
André, T., Elez, E., Van Cutsem, E., Jensen, L.H., Bennouna, J., Mendez, G., et al. (2024) Nivolumab Plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. New England Journal of Medicine, 391, 2014-2026. [Google Scholar] [CrossRef] [PubMed]
|
|
[100]
|
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)结直肠癌诊疗指南2025[M]. 北京: 人民卫生出版社, 2025.
|
|
[101]
|
Hu, H., Kang, L., Zhang, J., Wu, Z., Wang, H., Huang, M., et al. (2022) Neoadjuvant PD-1 Blockade with Toripalimab, with or without Celecoxib, in Mismatch Repair-Deficient or Microsatellite Instability-High, Locally Advanced, Colorectal Cancer (PICC): A Single-Centre, Parallel-Group, Non-Comparative, Randomised, Phase 2 Trial. The Lancet Gastroenterology & Hepatology, 7, 38-48. [Google Scholar] [CrossRef] [PubMed]
|
|
[102]
|
de Gooyer, P.G.M., Verschoor, Y.L., van den Dungen, L.D.W., Balduzzi, S., Marsman, H.A., Geukes Foppen, M.H., et al. (2024) Neoadjuvant Nivolumab and Relatlimab in Locally Advanced MMR-Deficient Colon Cancer: A Phase 2 Trial. Nature Medicine, 30, 3284-3290. [Google Scholar] [CrossRef] [PubMed]
|
|
[103]
|
Cao, W., Hu, H., Li, J., Wu, Q., Shi, L., Li, B., et al. (2023) China Special Issue on Gastrointestinal Tumors‐Radiological Features of Pathological Complete Response in Mismatch Repair Deficient Colorectal Cancer after Neoadjuvant PD‐1 Blockade: A Post Hoc Analysis of the PICC Phase II Trial. International Journal of Cancer, 153, 1894-1903. [Google Scholar] [CrossRef] [PubMed]
|
|
[104]
|
Chalabi, M., Fanchi, L.F., Dijkstra, K.K., Van den Berg, J.G., Aalbers, A.G., Sikorska, K., et al. (2020) Neoadjuvant Immunotherapy Leads to Pathological Responses in MMR-Proficient and MMR-Deficient Early-Stage Colon Cancers. Nature Medicine, 26, 566-576. [Google Scholar] [CrossRef] [PubMed]
|
|
[105]
|
Huang, W. and Zhang, S. (2024) A Watch-And-Wait Approach for Metachronous Multiple Colon Cancer Following Neoadjuvant Immunotherapy: A Case Report. Frontiers in Immunology, 15, Article 1391038. [Google Scholar] [CrossRef] [PubMed]
|
|
[106]
|
Orhan, A., Justesen, T.F., Raskov, H., Qvortrup, C. and Gögenur, I. (2024) Introducing Neoadjuvant Immunotherapy for Colorectal Cancer. Annals of Surgery, 281, 95-104. [Google Scholar] [CrossRef] [PubMed]
|
|
[107]
|
Zhao, M.H., Sun, T.T., Wang, L., Huang, Y.L., Xie, X.Y., Lu, Y., et al. (2024) Reassessment of Practice of Chinese Surgeons since Introduction of the Watch and Wait Strategy after Neoadjuvant Therapy for Rectal Cancer. Chinese Journal of Gastrointestinal Surgery, 27, 383-394. (In Chinese)
|
|
[108]
|
Nabekura, T., Sato, Y., Hiruta, N., Kitahara, N., Moriyama, Y., Kadoya, K., et al. (2025) Successful Treatment of Locally Advanced Microsatellite Instability-High Ascending Colon Cancer Using an Immune Checkpoint Inhibitor without Extensive Resection: A Case Report. Surgical Case Reports, 11, Article ID: cr.25-0007. [Google Scholar] [CrossRef] [PubMed]
|
|
[109]
|
Cercek, A., Foote, M.B., Rousseau, B., Smith, J.J., Shia, J., Sinopoli, J., et al. (2025) Nonoperative Management of Mismatch Repair-Deficient Tumors. New England Journal of Medicine, 392, 2297-2308. [Google Scholar] [CrossRef] [PubMed]
|
|
[110]
|
Cercek, A., Lumish, M., Sinopoli, J., Weiss, J., Shia, J., Lamendola-Essel, M., et al. (2022) PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. New England Journal of Medicine, 386, 2363-2376. [Google Scholar] [CrossRef] [PubMed]
|
|
[111]
|
Mi, M., Ye, C. and Yuan, Y. (2022) Neoadjuvant PD-1 Blockade: A Promising Nonoperative Strategy for Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. Signal Transduction and Targeted Therapy, 7, Article No. 361. [Google Scholar] [CrossRef] [PubMed]
|
|
[112]
|
Chen, G., Jin, Y., Guan, W., Zhang, R., Xiao, W., Cai, P., et al. (2023) Neoadjuvant PD-1 Blockade with Sintilimab in Mismatch-Repair Deficient, Locally Advanced Rectal Cancer: An Open-Label, Single-Centre Phase 2 Study. The Lancet Gastroenterology & Hepatology, 8, 422-431. [Google Scholar] [CrossRef] [PubMed]
|
|
[113]
|
Diaz, L.A., Shiu, K., Kim, T., Jensen, B.V., Jensen, L.H., Punt, C., et al. (2022) Pembrolizumab versus Chemotherapy for Microsatellite Instability-High or Mismatch Repair-Deficient Metastatic Colorectal Cancer (KEYNOTE-177): Final Analysis of a Randomised, Open-Label, Phase 3 Study. The Lancet Oncology, 23, 659-670. [Google Scholar] [CrossRef] [PubMed]
|
|
[114]
|
Wang, C. and Fakih, M. (2021) Targeting MSS Colorectal Cancer with Immunotherapy: Are We Turning the Corner? Expert Opinion on Biological Therapy, 21, 1347-1357. [Google Scholar] [CrossRef] [PubMed]
|
|
[115]
|
Yuan, J., Li, J., Gao, C., Jiang, C., Xiang, Z. and Wu, J. (2022) Immunotherapies Catering to the Unmet Medical Need of Cold Colorectal Cancer. Frontiers in Immunology, 13, Article 1022190. [Google Scholar] [CrossRef] [PubMed]
|
|
[116]
|
Wang, M., Wang, S., Desai, J., Trapani, J.A. and Neeson, P.J. (2020) Therapeutic Strategies to Remodel Immunologically Cold Tumors. Clinical & Translational Immunology, 9, e1226. [Google Scholar] [CrossRef] [PubMed]
|
|
[117]
|
Lin, Z.Y., Zhang, P., Chi, P., Xiao, Y., Xu, X.M., Zhang, A.M., et al. (2024) Neoadjuvant Short-Course Radiotherapy Followed by Camrelizumab and Chemotherapy in Locally Advanced Rectal Cancer (UNION): Early Outcomes of a Multicenter Randomized Phase III Trial. Annals of Oncology, 35, 882-891. [Google Scholar] [CrossRef] [PubMed]
|
|
[118]
|
Zhang, H., Li, Y., Xia, F., Sun, Y., Shen, L., Wan, J., et al. (2024) Study Protocol of Short-Course Radiotherapy Combined with CAPOX and PD-1 Inhibitor for Locally Advanced Colon Cancer: A Randomised, Prospective, Multicentre, Phase II Trial (TORCH-C). BMJ Open, 14, e079442. [Google Scholar] [CrossRef] [PubMed]
|
|
[119]
|
王一鸣, 焦旸. 局部进展期直肠癌新辅助放疗联合免疫治疗的现状与挑战[J]. 肿瘤学杂志, 2025, 31(8): 657-663.
|
|
[120]
|
万欣怡, 司徒颖婷, 张炜力, 等. 错配修复完整/微卫星稳定型结直肠癌肝转移免疫治疗研究进展[J]. 消化肿瘤杂志(电子版), 2026, 18(1): 28-37.
|
|
[121]
|
蒋海涛, 许阳贤. 抗血管生成靶向药物在治疗结直肠癌的耐药机制研究进展[J]. 中国临床药理学与治疗学, 2025, 30(2): 193-199.
|
|
[122]
|
刘秀. 转移性结直肠癌的化疗方案探索[D]: [博士学位论文]. 北京: 北京协和医学院, 2023.
|
|
[123]
|
刘婧禹, 尹桐, 吴玥, 等. 转移性结直肠癌三线治疗的研究现状及进展[J]. 中国癌症杂志, 2025, 35(11): 1056-1066.
|
|
[124]
|
涂娟娟, 金志明. 免疫检查点抑制剂治疗转移性结直肠癌的研究进展[J]. 上海交通大学学报(医学版), 2023, 43(2): 250-255
|
|
[125]
|
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., et al. (2023) Metastatic Colorectal Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 34, 10-32. [Google Scholar] [CrossRef] [PubMed]
|
|
[126]
|
Yoshino, T., Argilés, G., Oki, E., Martinelli, E., Taniguchi, H., Arnold, D., et al. (2021) Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Diagnosis Treatment and Follow-Up of Patients with Localised Colon Cancer. Annals of Oncology, 32, 1496-1510. [Google Scholar] [CrossRef] [PubMed]
|
|
[127]
|
姚宏伟, 孙应实, 张晓燕, 等. 结直肠癌多学科综合治疗协作组诊疗模式中国专家共识(2023版) [J]. 中国实用外科杂志, 2024, 44(1): 1-16.
|
|
[128]
|
中国抗癌协会, 中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-直肠癌(2024版) [J]. 中华结直肠疾病电子杂志, 2025, 14(1): 1-19.
|